Bo Gong et al. find two secretory PD-L1 splicing variants lacking transmembrane domains in aPD-L1-resistant NSCLC patients, which can mediate resistance to PD-L1 antibody blockade treatment by inhibiting T cell activity [310]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.